BIOMAT Database Logo BIOMAT Database Logo

[Physostigmine for treatment of central anticholinergic syndrome: a report of 3 cases (author's transl)]. 1980

K L Tan, and H N Lin, and J P Lu, and C C Chen

UI MeSH Term Description Entries
D008297 Male Males
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D002493 Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. CNS Disease,Central Nervous System Disease,Central Nervous System Disorder,CNS Diseases,Central Nervous System Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000931 Antidotes Agents counteracting or neutralizing the action of POISONS. Antidote,Theriacs

Related Publications

K L Tan, and H N Lin, and J P Lu, and C C Chen
[The use of physostigmine in the treatment of central anticholinergic intoxication (author's transl)].
July 1981, Der Anaesthesist,
K L Tan, and H N Lin, and J P Lu, and C C Chen
Central anticholinergic syndrome or central physostigmine responsive syndrome?
November 1997, European journal of anaesthesiology,
K L Tan, and H N Lin, and J P Lu, and C C Chen
Physostigmine: going ... going ... gone? Two cases of central anticholinergic syndrome following anaesthesia and its treatment with physostigmine.
July 1997, European journal of anaesthesiology,
K L Tan, and H N Lin, and J P Lu, and C C Chen
Hepatic encephalopathy--a physostigmine-reactive central anticholinergic syndrome?
February 1999, European journal of anaesthesiology,
K L Tan, and H N Lin, and J P Lu, and C C Chen
[Case report about central effects of physostigmine (author's transl)].
July 1980, Der Anaesthesist,
K L Tan, and H N Lin, and J P Lu, and C C Chen
The central anticholinergic syndrome: management with physostigmine.
March 1975, The Journal of the Kentucky Medical Association,
K L Tan, and H N Lin, and J P Lu, and C C Chen
[Felty's syndrome--report of 3 cases (author's transl)].
November 1980, Zhonghua nei ke za zhi,
K L Tan, and H N Lin, and J P Lu, and C C Chen
[Fahr's syndrome: a report on 3 cases (author's transl)].
August 1978, Der Nervenarzt,
K L Tan, and H N Lin, and J P Lu, and C C Chen
[Central anticholinergic syndrome and its therapy with physostigmine].
November 1975, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
K L Tan, and H N Lin, and J P Lu, and C C Chen
Reversal of central anticholinergic syndrome in man by physostigmine.
November 1968, JAMA,
Copied contents to your clipboard!